Chinese researchers are conducting a trial to see if mixing Covid-19 vaccines that use different technologies is safe and whether it could boost immunity. A trial began earlier this month to give a first dose of the adenovirus-vectored vaccine made by CanSino Biologics, followed by a protein subunit vaccine produced by Anhui Zhifei Longcom Biopharmaceutical, according to a clinical trials registration site run by a department under the US National Institutes of Health.…

This data comes from the ChinaPulse.com media intelligence and smart news insights monitoring platform.